The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Agree IK. The BOD not interested even at the all-time low. Totally baffling.
Billyb, Maybe those shrewd enough to buy in at around 4p are taking the money and running. Basu and his BOD missed out there. Seems they will not buy in at ANY price.
Dumbolina.
The new CFO seemed to have forced change to a greater focus on cash and costs, standard but missing under Bulmer.
Interesting the use of ebitda, Buffett correctly believes ignoring some costs in a business doesn't represent reality.
More importantly there is a real issue in not treating capitalisation and amortization in the same way and taken out. So include capitalisation to increase profit and ignore amortization to increase profit.
Considerably more sells than buys today. Is the trendy spike over now? Just wondering.
With loan note holders having the opportunity to convert into stock it is absolutely in shareholder interests for Basu to be talking up our stock!
The momentum is with us for a change. Long may it continue.
HXXps://www.proactiveinvestors.co.uk/companies/news/1040013/kromek-group-s-positive-trajectory-insights-from-ceo-arnab-basu-icymi-1040013.html
....
Stephen Gunnion (SG): Arnab, Kromek's interim results indicate a strong first half with notable financial improvements. Can you elaborate on these achievements?
Arnab Basu (AB): Absolutely, Stephen. We've experienced a period of positive momentum, underpinned by a significant improvement in our EBITDA position and reduced pre-tax losses.
This success stems from our unwavering focus on profitability, achieved through diligent cost control and enhancing our business margins. Our growth has been particularly robust in the advanced imaging and CBRN segments, reflecting our alignment with market demands and our strategic initiatives in these areas.
SG: Could you dive deeper into the growth drivers within your main business segments?
AB: Certainly. Our advanced imaging segment, especially in SPECT and CT modalities, has seen increasing adoption of our CZT material, revolutionizing digital spectrums and enhancing diagnostic capabilities. This trend is underscored by new product launches and significant partnerships, such as our collaboration with a CT Original Equipment Manufacturer (OEM) and Spectrum Dynamics' launch of a new product.
On the CBRN front, global security concerns have spiked demand for our handheld radiation detection tools. Our contract wins and robust pipelines in this segment, alongside partnerships for biosecurity projects with the US and UK governments, mark our strategic advancements and readiness to meet evolving market needs.
SG: With the momentum built in the first half, how do you anticipate this will impact Kromek's performance moving into the full year 2024?
AB: The trajectory we've set in the first half is expected to continue, with the second half traditionally being stronger for us. We're on track to achieve record revenues, a testament to our growth strategy's effectiveness.
Our focus remains on cost control and margin improvement, positioning us to report not only significant revenue growth but also a positive EBITDA for the year. This marks a pivotal step towards our long-term profitability and underscores our commitment to delivering value.
Just register here to read:
https://www.kromek.com/investor-relations/research/
Secular downtrend from 30/7/21, broken which is bullish, and sp, has broken above previous two price peaks, which confirms the bullish scenario. The RSI(relative strength index), is approaching the overbought region, of previous RSI, highs. However volatility based Bollinger bands are separating, signifying a fast sp, movement. If the lower Bollinger band which is currently going down, begins to turnup, expect a possible retracement, in sp.
Do you have link pls?
Interesting Cavendish note today with value up to 50p on a number of measurements.
GLA
Another bit of radiation detectors news and recognition.
At the Kmk webcast last week it was stated the Kmks handheld detectors were the fastest and most sensitive commercially available.today and that they have had an AI dept for some time working along side others depts.
All good news and recognition of Kmk advanced tech.
Https://www.insidermedia.com/news/north-east/kromek-lands-1.3m-for-radiation-sensor-project
"Sedgefield-based detection technology developer Kromek has won a £1.3m grant to develop an AI-powered radiation sensor."
Led by DTU Space, the i-RASE project is a collaboration between industrial and academic partners in Denmark, Germany, Norway and Italy to design, build and test a new class of radiation sensor based on cadmium zinc telluride and other advanced technologies.
Your wrong Billy. I just liked Mikes post just now to show you it was not me the first time, and to be honest i do not pretend to even guess the identity of whoever liked my post, its not really important. It wasn't you was it :)
And vice versa ……
I would hazard a guess that mike33 is recommending your blogs, vas. Hmmm
Sorry lost a few words
much larger award from SMITHS.
Also Mike,
Regarding the RNS dated 31/10/23 relating to three more order wins - it states that two are for nuclear security and Interestingly the third is ..." for the further development of the Group’s bio-security technology.", so chemical.
Just a month prior to this RNS from KMK ( 25th Sept 23) an award was made for the BOSKER PROJECT , to SMITHS INDUSTRY for contract of value £87,589,565 !!
https://www.smiths.com/news-and-insights/news/2023/uk-mod-awards-smiths-detection-contract-to-develop-and-supply-chemical-detection-capability#:~:text=LONDON%2C%20UK%2C%206%20October%202023,Sense%20Equipment%20for%20the%20UK
Could the initial relatively small award for Chemical defence made by KMK on 31st Oct 23 be just the start of a much larger award.
GL Vas
https://www.contractsfinder.service.gov.uk/notice/2a735898-efa1-4560-a946-def3d4786c09
Hi Vascular, good find I can't remember seeing that before.
The UK's MoD was mentioned from memory and other pipelines of opportunities. and the growing number of countries that have placed initial orders to evaluate etc.
But the 100 mil was mainly talked of.
Maybe the recent additional design functionality of the D5 system is linked to these tenders.
Do you remember this tender being put back due to an error ? In the documentation. It's dragged on a while this.
There were also other imaging contacts mentioned and crossing the t' and dotting the it's, very busy general it seems.
But some people always find something negative to make up or moan about eh?
HI MIKe,
Do they mean the Radiological Nuclear (RN) Detection Framework Agreement when they mention tender for 100m or some other.
This tender on Bidstas was published on 21 Dec 2023 for Delivery
01 Jun 2024 to 31 May 2028
Deadline
31 Jan 2024 .
https://bidstats.uk/tenders/2023/W51/813105477
Dear me Mike.
You really do need to read what you have written.
I have stated absolute facts, stating an unweighted pipeline that is open to a win rate and time execution (all of which is outside the current year time period I posted about) as a counter argument isn't a fact.
you don't half talk some tosh skid,
did you bother to listen to the company webcast ...i guess not..as you couldn't be ****d last time for some reason.
so you aren't aware of the 100 million live tenders out for d3/5 handheld detectors. i'd have thought if someone was going to endless moan about the company and its management it might be wise to have all the facts.
Mrlofer.
It's interesting that the chairman bought at a much higher level when he had just joined. Now he's in and knows basu and the company he not ?
We are outside a restricted period so why not ?
Whilst there are some positive signs in the numbers there are still a lot of red flags (the simply ridiculous stock levels, the aggressive accounting on intangibles etc).
Top line growth (and the mix to r&d from product) in H1 not where it should be to scale the p&l even on the lower cost base. H2 must be hit, in the past we have had basu stating h2 was in the bag only to come up really short with excuses - we can then look at the year in totality (and with the detailed notes in the annual report).
Jury's out.
Just a reminder,the big talk up from Basu back in 2016/2017 produced an sp in the 30-40p range. The sp in that context "remains in the gutter" when below 10p.. Promises and boasts from Kromek now are therefore treated with little trust by those of us who in the past accepted the "claims" coming out of Durham.
If timed well with a positive RNS at 10p then 25p will arrive quickly
Another good day for kmk. The leader of the armchair saddos on advfn is not moaning that directors have not bought….sometimes there are perfectly good reasons all imo dyor …..